Addition of Niraparib to Best Supportive Care as Maintenance Treatment in Patients with Advanced Urothelial Carcinoma Whose Disease Did Not Progress After First-line Platinum-based Chemotherapy: The Meet-URO12 Randomized Phase 2 Trial

Meet-URO12 was a randomized phase 2 trial testing the poly-ADP ribose-polymerase (PARP) inhibitor niraparib as maintenance treatment in patients with advanced urothelial cancer after platinum-based chemotherapy. We did not demonstrate a significant improvement in progression-free survival. The conduction of a phase 3 trial with single agent niraparib in this population is not supported by these results.